Source: CureToday articles
Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.
Recent Content
- Op-Ed: Expand Patient Choice to Lower Medication Costs
- Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
- Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
- Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
- SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
- GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
- The Invisibility of Blood Cancers to Others
- Op-Ed: Prescribing Cascade Is Avoidable—If We Empower Pharmacists to Intervene
- MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma
- Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression